Mural Oncology plc (MURA)

Market Cap	51.62M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	16.92M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	175,550
Open	3.080
Previous Close	3.110
Day's Range	2.950 - 3.080
52-Week Range	2.950 - 6.250
Beta	n/a
Analysts	Strong Buy
Price Target	14.00 (+359.02%)
Earnings Date	Aug 15, 2024

About MURA

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 119
• Stock Exchange: NASDAQ
• Ticker Symbol: MURA

Analyst Forecast

According to 2 analysts, the average rating for MURA stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 359.02% from the latest price.

Price Target

$14.0

(359.02% upside)

Analyst Consensus: Strong Buy